[go: up one dir, main page]

ES8301954A1 - Mejoras introducidas en un procedimiento para la obtencion del hidrocloruro de ranitidina - Google Patents

Mejoras introducidas en un procedimiento para la obtencion del hidrocloruro de ranitidina

Info

Publication number
ES8301954A1
ES8301954A1 ES505951A ES505951A ES8301954A1 ES 8301954 A1 ES8301954 A1 ES 8301954A1 ES 505951 A ES505951 A ES 505951A ES 505951 A ES505951 A ES 505951A ES 8301954 A1 ES8301954 A1 ES 8301954A1
Authority
ES
Spain
Prior art keywords
furan derivative
methyl
aminoalkyl
aminoalkyl furan
ethenediamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES505951A
Other languages
English (en)
Other versions
ES505951A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8301954(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ES505951A0 publication Critical patent/ES505951A0/es
Publication of ES8301954A1 publication Critical patent/ES8301954A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE HIDROCLORURO DE RANITINA. CONSISTE EN LA DISOLUCION DE RATIDINA EN ALCOHOL METILADO CON CLORURO DE HIDROGENO, EN PRESENCIA DE ACETATO DE ETILO, SEGUIDA DE CRISTALIZACION DEL HIDROCLORURO DE RANITIDINA EN EL MISMO DISOLVENTE, EN CONDICIONES TALES QUE SE PRODUZCA LA FORMA 2 DEL HIDROCLORURO DE RANITIDINA. ESTOS COMPUESTOS TIENEN APLICACIONES FARMACOLOGICAS PARA EL TRATAMIENTO DE LA ACIDEZ GASTRICA, LA ULCERA PEPTICA Y DE ESTADOS ALERGICOS E INFLAMATORIOS.
ES505951A 1980-10-01 1981-10-01 Mejoras introducidas en un procedimiento para la obtencion del hidrocloruro de ranitidina Expired ES8301954A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01

Publications (2)

Publication Number Publication Date
ES505951A0 ES505951A0 (es) 1983-01-01
ES8301954A1 true ES8301954A1 (es) 1983-01-01

Family

ID=10516407

Family Applications (1)

Application Number Title Priority Date Filing Date
ES505951A Expired ES8301954A1 (es) 1980-10-01 1981-10-01 Mejoras introducidas en un procedimiento para la obtencion del hidrocloruro de ranitidina

Country Status (29)

Country Link
US (2) US4521431A (es)
JP (1) JPS5791983A (es)
KR (1) KR870001431B1 (es)
AT (1) AT389696B (es)
AU (1) AU549119B2 (es)
BE (1) BE890574A (es)
CA (1) CA1202638A (es)
CH (1) CH652122A5 (es)
CZ (1) CZ280885B6 (es)
DE (1) DE3139134A1 (es)
DK (2) DK167794B1 (es)
ES (1) ES8301954A1 (es)
FR (1) FR2491067A1 (es)
GR (1) GR72499B (es)
HK (1) HK97985A (es)
IE (1) IE51604B1 (es)
IL (1) IL63968A (es)
IT (1) IT1143237B (es)
KE (1) KE3549A (es)
LU (1) LU83661A1 (es)
MY (1) MY8500747A (es)
NL (1) NL8104482A (es)
NZ (1) NZ198522A (es)
PH (2) PH19489A (es)
PT (1) PT73744B (es)
SE (1) SE453500B (es)
SK (1) SK277922B6 (es)
ZA (1) ZA816809B (es)
ZW (1) ZW24481A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162525C (da) * 1983-07-15 1992-03-30 Richter Gedeon Vegyeszet Fremgangsmaade til fremstilling af ranitidin-hydroklorid
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
CN1055090C (zh) * 1993-03-12 2000-08-02 法玛西雅厄普约翰美国公司 结晶性头孢噻夫游离酸
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
EP0754182A1 (en) * 1994-04-08 1997-01-22 Brantford Chemicals Inc. Form 1 ranitidine hydrochloride with increased density
HU226827B1 (en) 1994-04-15 2009-11-30 Upjohn Co Novel crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-piridinyl]piperazine
IN181698B (es) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
IN181699B (es) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP1178041A1 (en) * 1994-05-18 2002-02-06 Aventis Pharmaceuticals Inc. Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives
EP0694540B1 (en) 1994-06-24 1998-08-19 Ranbaxy Laboratories Limited Process for the manufacture of form 1 ranitidine hydrochloride
CA2201735A1 (en) * 1994-11-18 1996-05-30 The Upjohn Company A new physically stable solid form of a fluoroquinolone
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
WO1997035853A1 (en) * 1996-03-25 1997-10-02 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
DK0903345T3 (da) 1997-08-08 2000-10-23 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
AU2003286889A1 (en) * 2002-11-08 2004-06-03 Dov Pharmaceutical, Inc. Polymorphs of bicifadine hydrochloride
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
EP2719384B1 (en) 2005-07-27 2018-08-08 Otsuka America Pharmaceutical, Inc. Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
AU2007309534B2 (en) * 2006-10-20 2012-08-16 Scinopharm Singapore Pte, Ltd. Process for making crystalline anhydrous docetaxel
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
US9006434B2 (en) 2011-06-30 2015-04-14 Toray Industries, Inc. Crystals of glycine derivative and pharmaceutical use thereof
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN106432147B (zh) * 2015-05-26 2018-04-17 烟台市华文欣欣医药科技有限公司 一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DK167923B1 (da) 1994-01-03
CZ403591A3 (en) 1994-01-19
IE51604B1 (en) 1987-01-21
LU83661A1 (fr) 1983-06-08
KR870001431B1 (ko) 1987-08-06
AU7595581A (en) 1982-04-08
IE812287L (en) 1982-04-01
HK97985A (en) 1985-12-13
CH652122A5 (fr) 1985-10-31
FR2491067B1 (es) 1984-09-07
FR2491067A1 (fr) 1982-04-02
IL63968A0 (en) 1981-12-31
PH19489A (en) 1986-05-14
DE3139134C2 (es) 1990-04-19
PH21761A (en) 1988-02-18
ZW24481A1 (en) 1983-04-27
ZA816809B (en) 1983-05-25
CA1202638A (en) 1986-04-01
US4521431A (en) 1985-06-04
US4672133A (en) 1987-06-09
AU549119B2 (en) 1986-01-16
SE8105812L (sv) 1982-04-02
PT73744B (en) 1983-10-31
NL8104482A (nl) 1982-05-03
PT73744A (en) 1981-10-01
IT1143237B (it) 1986-10-22
JPH0443070B2 (es) 1992-07-15
DK436281A (da) 1982-04-02
GR72499B (es) 1983-11-15
KR830007070A (ko) 1983-10-14
DK33792A (da) 1992-03-12
SK403591A3 (en) 1995-08-09
KE3549A (en) 1985-08-16
MY8500747A (en) 1985-12-31
DE3139134A1 (de) 1982-05-19
CZ280885B6 (cs) 1996-04-17
IT8149407A0 (it) 1981-10-01
IL63968A (en) 1985-10-31
ES505951A0 (es) 1983-01-01
SK277922B6 (en) 1995-08-09
DK167794B1 (da) 1993-12-13
SE453500B (sv) 1988-02-08
NZ198522A (en) 1985-07-12
DK33792D0 (da) 1992-03-12
BE890574A (fr) 1982-04-01
ATA422281A (de) 1989-06-15
AT389696B (de) 1990-01-10
JPS5791983A (en) 1982-06-08

Similar Documents

Publication Publication Date Title
ES8301954A1 (es) Mejoras introducidas en un procedimiento para la obtencion del hidrocloruro de ranitidina
IL53520A (en) Derivatives of 5-(3,4-dihydroxy phenyl)2-oxazolidinones (and 2-thiazolidinones)and thiones and a process for their production
IE43731L (en) Triazolyl and imidazolyl derivatives
ES456610A1 (es) Procedimiento para preparar derivados de sulfonamida.
JPS5484564A (en) Novel gamma-butyrolactone derivative and its preparation
ES8306147A1 (es) Un procedimiento para la preparacion de derivados de oxazolidin-2,4-diona 5-heterociclico-sustituidos.
IL58300A (en) Substituted furan derivatives of cyano-and nitroguanidine and of 1,1-diamino-2-cyano-and-nitroethylene and their preparation
AU583311B2 (en) N-(6-Methoxy-5-(perfluoroalkyl)-1-naptholyl)-N- methylglycines and their thionaphthoyl analogs
GB2015524A (en) Pyridine derivatives
IL70401A (en) N(2-((5-(tricycloalkylamino-methyl)-2-furanyl)-methyl-thio)-ethyl) n'-2-nitro-1,1-ethenediamine derivatives,their preparation and pharmaceutical compositions containing them
MX152489A (es) Mejoras a camara de combustion de lecho fluidizado
NO164771C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminopropanolderivater.
IL64210A0 (en) 5-phenyltetrazoles containing basic substituents,a process for their preparation and their use as drugs
PT76760A (en) A process for the preparation of n-<2-<<<5-(dimethylamino)methyl-2-furanyl>methyl>thio>ethyl>-n'-methyl-2-nitro-1,1-ethenediamine
ES8401951A1 (es) Un procedimiento para la preparacion de derivados de bencenosulfonamidas.
JPS53108936A (en) Epolysuccinic monoester derivative
IT8026361A0 (it) Procedimento di preparazione della n-[2-[[[5-(dimetilamino)-metil-2-fu ranil]-metil]-ito]-etil]-n'-metil-2-nitro-1,1-etilendiamina
JPS56152476A (en) Novel minimycin derivative
GB2001531A (en) Organic compounds
JPS5265264A (en) Preparation of furan derivatives
JPS5334779A (en) Novel piperazine derivatives and thier preparation
ES543966A0 (es) Procedimiento para la preparacion de la n-(2-(((5-(dimetila-mino)-metil-2-furanil)metil)tio)etil)-n'-metil-2-nitro-1,1- etendiamina
ES8200358A1 (es) Procedimiento para la obtencion de la n-2-5-(dimetilamino)metil-2-furanil metil tio-n-metil-2-nitro-1,1-etenodiamina .
NO146239C (no) Mellomprodukt for fremstilling av 6,7-dimetoksy-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolin med blodtrykksenkende virkning
JPS52131588A (en) N-substituted trimethoxybenzylpiperazine derivatives

Legal Events

Date Code Title Description
GD1A Contractual licences

Effective date: 19960910

GC1A Exploitation certificate registered application without search report

Effective date: 19960904

GD1A Contractual licences

Effective date: 19960910